Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
After Prior TNFi in axSpA, Taking Secukinumab or Another TNFi Appear Equivalent
Key clinical point: After stopping a tumor necrosis factor inhibitor (TNFi), there is no advantage seen for starting the anti–IL-17 biologic secukinumab over another TNFi in axial spondyloarthritis.
Major finding: After adjustment, the drug survival rate after switching was not significantly different between taking another TNFi or secukinumab.
Data Source: A retrospective analysis of 382 axSpA patients in the Swiss Clinical Quality Management Cohort who were candidates for a new biologic after discontinuing a previous TNFi.
Disclosures: Dr. Ciurea reported multiple financial relationships with pharmaceutical companies but received no funding for this study.
Tellenbach C et al. Ann Rheum Dis. 2019;78(Suppl 2):197. Abstract OPO237, doi: 10.1136/annrheumdis-2019-eular.2427